Pulmonary hypertension (PH) is a rare, but life-threatening, adverse event in patients treated with tyrosine kinase inhibitors (TKIs), such as dasatinib, but has not been fully evaluated in patients treated with imatinib or nilotinib. We used echocardiography to noninvasively assess the incidence of PH in 105 patients with chronic myeloid leukaemia (CML) treated with imatinib (n = 37), nilotinib (n = 30) or dasatinib (n = 38). The mean triscupid regurgitation peak gradient (TRPG), which reflects pulmonary arterial pressure, was 22Á7 mmHg in the imatinib group, 23Á1 mmHg in the nilotinib group and 23Á4 mmHg for dasatinib group. These values were not significantly different, but higher than those (19Á0 mmHg) in newly diagnosed CML patients. A TRPG > 31 mmHg, marking possible PH onset, was detected in 9 of 105 patients: one (2Á7%) treated with imatinib, three (10Á0%) with nilotinib and five (13Á2%) with dasatinib. Only three patients complained of dyspnoea, whereas the other six were asymptomatic. In addition, there was a tendency toward correlation of TRPG value and age or TKI treatment duration. These results suggested that treatment with not only dasatinib, but also imatinib and nilotinib, can be associated with subclinical PH. Noninvasive echocardiography is useful for screening, especially in older patients with long-term TKI treatment.
In recent decades, tyrosine kinase inhibitors (TKIs) have dramatically improved the outcomes of patients with chronic myeloid leukaemia (CML) (Druker et al, 2006; Larson et al, 2012; Jabbour et al, 2014; Jain et al, 2016) . TKIs have been developed to directly target BCR-ABL1 (Druker et al, 2001) , therefore, these drugs may cause less incidence and severity of adverse event (AE). Nevertheless, TKIs can cause serious or even life-threatening AEs, such as fluidic retention, cardiotoxicity, hepatic toxicity and cytopenias (Jabbour et al, 2010; Deininger et al, 2014; Ong et al, 2015; Fossard et al, 2016) .
Recently, fatal pulmonary hypertension (PH) has been reported sporadically in CML patients treated with TKIs. PH, presumably induced by TKIs, was first reported in a patient receiving dasatinib in 2007 (Quintas-Cardama et al, 2007) . In subsequent case reports, the majority of patients with PH onset had been treated with dasatinib (Mattei et al, 2009; Rasheed et al, 2009; Dumitrescu et al, 2011; Hennigs et al, 2011; Montani et al, 2012; Orlandi et al, 2012; Sano et al, 2012; Zakrzewski et al, 2012; Yun et al, 2014; Hong et al, 2015; Shah et al, 2015; Wang et al, 2015; Morishita et al, 2016; Nagasaki et al, 2016) . After discontinuation of dasatinib, PH symptoms improved in the majority of patients, with reversal of pulmonary vasculopathy. Therefore, it is conceivable that PH may be a complication specifically associated with dasatinib. On the other hand, TKIs possess the indirect pleiotropic biological "off-target" effects to inhibit other tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR) (Barst, 2005; Ghofrani et al, 2005; Schermuly et al, 2005; Seferian & Simonneau, 2013) . Therefore, by inhibiting vascular remodelling, TKIs could theoretically be effective for treating PH. Several clinical trials have reported a significant decrease in pulmonary vascular resistance and improvement of PH in patients who were given imatinib (Ghofrani et al, 2010; Hoeper et al, 2013; Frost et al, 2015) . To clarify the contradictory effects of TKIs, we used echocardiography to noninvasively screen CML patients who have been given imatinib, nilotinib or dasatinib. We assessed the incidence of TKI-associated PH and subclinical PH, and analysed the factors associated with onset of PH.
Methods

Patients
A total of 105 patients with CML in chronic phase (CP) who received TKI were enrolled in this study between 2014 and 2015 (Table I) . Patients who had prior or concurrent congenital heart disease, pulmonary embolism or connective tissue disease at the time of enrolment were excluded from this study. No patient had a family history of PH. Nine control patients with newly diagnosed CML in CP prior to TKI treatment were also evaluated by echocardiography (Table I) .
This study was conducted in accordance with the Declaration of Helsinki and its amendments, and the Ethical Guidelines for Epidemiological Research by the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labour and Welfare of Japan. The protocol was approved by the Ethics Committee of Kyushu University Graduate School and Faculty of Medicine (approval no. 26-317). All patients gave informed consent.
Echocardiographic evaluation
According to the guidelines, a definitive diagnosis of PH is made by cardiac catheterization and is defined as an increase in mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest or >30 mmHg with exercise (Galie et al, 2009) . However, cardiac catheterization is an invasive examination, and is not feasible for PH screening of the many patients treated with TKIs who do not have any symptoms. In this study, echocardiographic screening was used to assess the possibility of PH onset. The tricuspid regurgitation peak gradient (TRPG), which is determined by continuous-wave Doppler echocardiography, has relatively significant correlations with right cardiac catheterization measurement of PAP (Yock & Popp, 1984) . According to the criteria by European Society of Cardiology, PH is suspected when the TRPG is >31 mmHg (Galie et al, 2009) . We determined the left ventricular ejection fraction (LVEF) to rule out left heart failure. Brain natriuretic peptide (BNP), which is correlated with mPAP (Yap et al, 2004) , was assayed in 87 patients.
Statistical analysis
In this study, we analysed the association of TRPG with age, CML disease duration, duration of TKI treatments, daily dosage of the current TKIs, BNP and LVEF. Comparisons of TRPG values in TKI groups and controls were performed by one-way analysis of variance (ANOVA) followed by Tukey's post hoc test. Pearson and Spearman correlation coefficients were used to determine the significance of relationships between TRPG values and age, duration, dosage, BNP and LVEF values. P-values <0Á05 were considered statistically significant. Analysis was performed using the EZR (Kanda, 2013) , a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
Fifty-one (48Á6%) out of the 105 patients continued with the same TKI during their whole clinical course; the remaining 54 (51Á4%) patients switched from the initial treatments to another because of the AEs, intolerance or resistance. For analysis, the patients were divided into three groups by the TKIs that they used at the time of study enrolment (Table I) : 37 patients were on imatinib, 30 on nilotinib and 38 on dasatinib. At evaluation of PH, the median patient age was 70Á5 years (range, 38-92) for imatinib, 62Á5 years (range, 24-85) for nilotinib and 54 years (range, 35-78) for dasatinib. The median age in the imatinib group was significantly higher than that in the other groups (P < 0Á05). The median duration of treatment with the TKI that was taken at the time of echocardiographic evaluation (Table I) was 84 months (range, 10-165) for imatinib, 27 months (range, 3-53) for nilotinib and 19Á5 months (range, 2-51) for dasatinib. The treatment duration was significantly longer for imatinib than for the second generation TKIs (P < 0Á05). The same trend was observed for the duration of CML disease, with a median of 115 months (range, 10-228) for imatinib, 46 months (range, 3-153) for nilotinib and 66Á5 months (range, 4-287) for dasatinib group, with that of the imatinib group being significantly longer (P < 0Á05).
Echocardiographic evaluation
Echocardiography found mean TRPG values of 22Á7 mmHg (range, 8-46) for imatinib, 23Á1 mmHg (range, 7-35) for nilotinib and 23Á4 mmHg (range, 11-40) for dasatinib. There were no significant differences in TRPG values among the three groups (P = 0Á887, Table I and Fig 1) . Of note, the mean TRPG was higher in patients taking TKIs at enrolment compared with that in the nine patients with newly diagnosed CML (mean TRPG, 19Á0 mmHg), but the difference was not significant (P = 0Á38). Nine of the 105 patients (8Á6%)
presented with an elevated TRPG > 31 mmHg, suggesting the presence of PH; 1 of 37 (2Á7%) on imatinib, 3 of 30 (10Á0%) on nilotinib and 5 of 38 (13Á2%) on dasatinib. The differences were not significant, and none of those patients underwent heart catheterization. The characteristics of the nine patients are shown in Table II , and discussed below.
Factors associated with TRPG elevation
To evaluate factors associated with TRPG elevation, we analysed the relationships between TRPG values and age, treatment duration with the current TKI, daily TKI dosage, months since CML diagnosis, BNP level and LVEF. As shown in Fig 2A, in patients taking nilotinib and dasatinib there was a weak correlation between older age and TRPG value (P = 0Á20, r = 0Á24 and P = 0Á13, r = 0Á25, respectively). TRPG was not correlated with age in the imatinib group (P = 0Á61, r = 0Á09). There was a weak correlation between duration of the current TKI treatment and TRPG value in the nilotinib group (P = 0Á17, r = 0Á26), but not in the imatinib and dasatinib groups (P = 0Á31, r = À0Á17 and P = 0Á81, r = À0Á04; Fig 2B) . TRPG value was not correlated with disease duration in any of the three TKI groups (Fig 2C) . There was a tendency toward an inverse relationship between TRPG values and TKI dose of imatinib Triscupid regurgitation peak gradient (TRPG) values in chronic myeloid leukaemia (CML) patients at diagnosis or with ongoing imatinib, nilotinib or dasatinib treatment. There was no difference among the imatinib, nilotinib and dasatinib groups (P = 0Á887) or between the tyrosine kinase inhibitor groups and newly diagnosed patients (controls) (P = 0Á38). The box plots indicate medians (solid lines) and outliers (dotted lines). (P = 0Á12, r = À0Á26), but not with nilotinib or dasatinib (P = 0Á78, r = 0Á05 and P = 0Á76, r = À0Á05; Fig 2D) . A significant correlation was observed for BNP and TRPG (P = 0Á0003, r = 0Á38 , Fig 3) , which is consistent with previous reports (Yap et al, 2004) . We assessed the relationship of LVEF with TRPG to rule out the possibility of PH onset by left heart dysfunction: no significant relationship between these two variables was found (P = 0Á83, r = À0Á021) (data not shown).
High white blood cell (WBC) and platelet counts at the onset of CML can be risk factors for developing PH (Adir & Humbert, 2010) . To evaluate the effects of hyperleucocytosis and thrombocytosis on elevation of TRPG, we serially measured TRPG values and obtained WBC and platelet counts at initial CML diagnosis and after TKI treatment in six out of nine newly diagnosed CML patients (Table I, Figure S1 ). We found no significant difference in the mean TRPG value of the 105 patients who had been taking TKIs and the nine newly diagnosed patients (P = 0Á38, Table I ). Despite rapid reductions of WBC and platelet counts with TKIs treatment, the difference in TRPG values before and after TKIs treatment was not significant ( Figure S1 ). These results suggest little impact of WBC or platelet counts on elevation of TRPG values in this study.
Clinical course of individual patients
The clinical courses of 105 patients are outlined in Fig 4A-C . Figure 4A shows the clinical courses of the 37 imatinibtreated patients. Twenty-six patients had been treated with imatinib only (70Á3%); 11 (29Á7%) had switched from interferon or other TKIs. Patients 30-37, whose disease was of relatively long duration, had initially been treated with interferon at CML diagnosis, because TKIs had not been 
Characteristics of nine patients with elevated TRPG values
Nine patients (Patients 26, 42, 62, 67, 68, 76, 81, 104 and 105) had elevated TRPG > 31 mmHg; three of them complained of dyspnoea (Table II) . There was no significant relationship between TRPG value and duration of TKI treatment (Fig 2B) .
The first patient with elevated TRPG (Patient 26) was a 67-year-old man, who was diagnosed with CML in 2003, and has received imatinib 400 mg daily for 12 years since his initial diagnosis (Fig 4A) . He experienced acute myocardial infarctions in 2002 and in 2009, and stents were implanted on both occasions. Since then, he has maintained normal LV systolic function. In 2015, he complained of sudden onset of exertional dyspnoea. Echocardiography revealed TRPG elevation of 46 mmHg, without obvious LV systolic dysfunction or any asynergy of LV wall motion. His BNP was elevated to 95Á1 pg/ml, and D-dimer was also high (9Á1 lg/ml). Pulmonary embolism was ruled out by computed tomographic scanning. Heart catheterization was not carried out. After imatinib discontinuation, the dyspnoea symptoms disappeared immediately; imatinib was restarted at a reduced dosage of 200 mg daily a month later. Echocardiographic reevaluation 2 months later showed a TRPG of 21 mmHg. He has remained asymptomatic under imatinib treatment and is being followed-up closely.
The second patient (Patient 76), a 62-year-old man diagnosed with CML in 2013, started treatment with dasatinib 100 mg daily. In August 2015, he complained of exertional dyspnoea. His TRPG value was elevated up to 35 mmHg by echocardiography. Heart catheterization was not carried out. Dyspnoea immediately disappeared after discontinuation of dasatinib. After 1 month, dasatinib was restarted at reduced dose of 70 mg, and he was then switched to bosutinib.
The third patient (Patient 81) was a 53-year-old woman, who was diagnosed with CML in 2008 and initially treated with imatinib. She was switched first to dasatinib and then to nilotinib because of haematological AEs (Table II, Fig 4C) . Since 2011, she had been treated with dasatinib 50 mg daily, which was well tolerated until 2013 when, after 17 months of dasatinib, she complained of progressive dyspnoea on exertion. On echocardiography her TRPG was elevated to 40 mmHg, indicating possible PH onset. LV systolic function was well preserved. BNP was slightly elevated at 29Á3 pg/ml and D-dimer was within the normal range. A definite diagnosis of PH was not made because the patient refused to undergo heart catheterization. Her symptoms promptly disappeared after cessation of dasatinib, and the TRPG decreased to 31 mmHg. After switching to nilotinib, the patient has had no apparent PH-associated symptoms.
Discussion
Dasatinib has provided excellent results in treating CML patients by achieving faster and deeper responses compared with imatinib (Jabbour et al, 2014) , however, it has been associated with serious PH (Montani et al, 2012; Shah et al, 2015) . Approximately 40 cases of PH onset during dasatinib treatment have been reported worldwide to date (Shah et al, 2015; Nagasaki et al, 2016) . Dasatinib-related PH usually resolves immediately after cessation of treatment, but it can be a fatal complication. Two deaths in France and one in Japan have been documented (Montani et al, 2012; Morishita et al, 2016) . PH is now regarded as one of the most serious AEs associated with dasatinib, but the cause is obscure. Montani et al (2012) reported that 13 patients treated between 2006 and 2010 with dasatinib in France developed PH, which was confirmed by cardiac catheterization. At that time, approximately 2900 patients were being treated with dasatinib in France, giving an estimated rate of PH occurrence of 0Á45%. In 2011, on the basis of these reports, the US Food and Drug Administration issued a warning of the risk of PH induced specifically by dasatinib, and recommended evaluating patients for signs and symptoms of cardiopulmonary disease before starting dasatinib and during the treatment (Sano et al, 2012) . In Korea, Lee et al (2013) prospectively evaluated TRPG by echocardiography in CML patients being treated with dasatinib. They found that eight of 66 patients (12Á1%) had a significant increase in right ventricular systolic pressure, which suggested possible PH onset. Seven of the patients had symptoms such as exertional dyspnoea, and PH onset was confirmed in two patients by cardiac catheterization. In our study, five of 38 patients (13Á2%) on dasatinib had TRPG values >31 mmHg (Table I) , a frequency consistent with that reported by the Korean group. Two of five patients (40%) with elevation of TRPG complained of exertional dyspnoea; three were asymptomatic. Cardiac catheterization was not performed in any patients (Table II) . All 33 patients on dasatinib with normal TRPG values were also asymptomatic. Although the TRPG values obtained by echocardiography might not be fully compatible with those by cardiac catheterization, the results suggested that noninvasive echocardiography is sensitive for screening PH and is also effective for easily screening groups of patients with suspect subclinical PH. A subsequent definite diagnosis of PH can be made by invasive cardiac catheterization. The French cohort study (Montani et al, 2012) retrospectively estimated the frequency of PH (~0Á45%) by targeting symptomatic patients who were then diagnosed by cardiac catheterization. PH might thus be found to occur much more often than expected if larger groups of asymptomatic patients were screened by echocardiography.
This study investigated the effects of dasatinib, imatinib and nilotinib on the development of PH. Surprisingly, echocardiography screening detected elevated TRPGs (>31 mmHg) not only in dasatinib-treated patients (13Á2%) but also in one of 37 patients (2Á7%) treated with imatinib and in three of 30 treated with nilotinib (10%). There were no significant differences in mean TRPG values among the three treatment groups, but their TRPG values were higher than that of the newly diagnosed patients. That indicates possible PH onset among patients treated with imatinib or nilotinib. To the best of our knowledge, there has been only one report of PH in a patient treated with nilotinib (Zakrzewski et al, 2012) , and no reports of PH associated with imatinib (Moslehi & Deininger, 2015) . No prospective study using echocardiographic screening of patients on imatinib or nilotinib treatment has been reported. Even though the study sample was small, and cardiac catheterization was not done, our study suggests that echocardiography is effective for assessing the possibility of PH onset in patients who have received any available TKIs.
The factors associated with dasatinib-induced PH have not been clarified. A report on PH in 41 patients receiving dasatinib demonstrated that duration of dasatinib treatment ranged from 1 week to 75 months (median, 31Á5 months), and dasatinib dosage was not correlated with PH onset (Shah et al, 2015) . Thus, we sought to find risk factors of PH onset associated with dasatinib as well as imatinib and nilotinib treatment. However, there were no significant correlations of TRPG elevation with age, TKI treatment duration, or dosage. BNP was the only factor closely associated with TRPG, thus, monitoring BNP would be helpful to predict PH. There were trends toward correlation of age and TRPG values in nilotinib-and dasatinib-treated patients, and treatment duration and TRPG values in nilotinib-treated patients. Thus careful attention might be required regarding PH onset for older patients with long TKI treatment duration. In the future, a larger cohort study including both echocardiography and heart catheterization would be desirable to clarify the actual incidence of PH and better evaluate factors associated with onset of PH among TKI-treated patients.
The pathophysiology of TKI-induced PH is unclear but PH is characterized by the proliferation and migration of pulmonary vascular smooth muscle cells (SMCs) (Schermuly et al, 2005; Rocha et al, 2007) . Recent evidence from animal models indicates that imatinib can suppress abnormal proliferation of SMCs by inhibiting PDGFR, resulting in improvement of PH (Schermuly et al, 2005) . In clinical trials, imatinib considerably improved pulmonary haemodynamics in symptomatic PH patients (Ghofrani et al, 2010; Hoeper et al, 2013; Frost et al, 2015) . In this study, imatinib dosage tended to inversely correlate with TRPG value, suggesting that imatinib might decrease pulmonary arterial blood pressure in a dose-dependent manner (Fig 2D) . In vitro studies have found that dasatinib inhibited PDGFR more strongly than imatinib, and inhibited Srk kinase, which has a potent effect on pulmonary vascular remodeling (Pullamsetti et al, 2012) . However, current observations in humans have demonstrated paradoxical effects of dasatinib treatment with relevance to the onset of PH (Moslehi & Deininger, 2015; Shah et al, 2015) . Guignabert et al (2016) reported that dasatinib caused pulmonary endothelial damage through production of mitochondrial reactive oxygen species, which increases susceptibility to PH development. They found that dasatinib treatment increased the risk of PH, but dasatinib alone was not sufficient to induce PH. They concluded that, in addition to dasatinib treatment, a second event, possibly genetic or environmental factors, might be necessary for PH to develop. Additional experimental and clinical studies are required to address this issue.
In conclusion, our study demonstrated high TRPG values in CML patients not only with dasatinib treatment but also with imatinib and nilotinib, suggesting that subclinical PH might be more common than expected in patients treated with any TKIs. Careful screening with echocardiography is necessary, especially for older patients who have received TKIs for a long time.
